These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1305 related articles for article (PubMed ID: 28550414)
21. Treatment outcomes of chronic-phase chronic myeloid leukemia with resistance and/or intolerance to a 1st-line tyrosine kinase inhibitor in Japan: the results of the New TARGET study 2nd-line. Sakurai M; Okamoto S; Matsumura I; Murakami S; Takizawa M; Waki M; Hirano D; Watanabe-Nakaseko R; Kobayashi N; Iino M; Mitsui H; Ishikawa Y; Takahashi N; Kawaguchi T; Suzuki R; Yamamoto K; Kizaki M; Ohnishi K; Naoe T; Akashi K; Int J Hematol; 2020 Jun; 111(6):812-825. PubMed ID: 32152876 [TBL] [Abstract][Full Text] [Related]
22. The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group. Iriyama N; Ohashi K; Hashino S; Kimura S; Nakaseko C; Takano H; Hino M; Uchiyama M; Morita S; Sakamoto J; Sakamaki H; Inokuchi K Intern Med; 2018 Jan; 57(1):17-23. PubMed ID: 29033428 [TBL] [Abstract][Full Text] [Related]
24. Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study. Iriyama N; Fujisawa S; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H Am J Hematol; 2015 Sep; 90(9):819-24. PubMed ID: 26103598 [TBL] [Abstract][Full Text] [Related]
25. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia. Abbott BL Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209 [TBL] [Abstract][Full Text] [Related]
26. Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic phase. Inokuchi K; Kumagai T; Matsuki E; Ohashi K; Shinagawa A; Hatta Y; Takeuchi J; Yoshida C; Wakita H; Kozai Y; Shirasugi Y; Fujisawa S; Iwase O; Yano S; Okamoto S; Oba K; Sakamoto J; Sakamaki H J Clin Exp Hematop; 2014; 54(3):197-204. PubMed ID: 25501110 [TBL] [Abstract][Full Text] [Related]
27. [Dasatinib treatment based on BCR- ABL mutation detection in imatinib- resistant patients with chronic myeloid leukemia]. Jiang Q; Qin Y; Lai Y; Jiang H; Shi H Zhonghua Xue Ye Xue Za Zhi; 2016 Jan; 37(1):7-13. PubMed ID: 26876246 [TBL] [Abstract][Full Text] [Related]
28. [Contemporary treatment methods of adult patients with BCR/ABL1 positive chronic myeloid leukemia]. Slezáková K; Mistrík M; Bátorová A Vnitr Lek; 2020; 66(4):214-224. PubMed ID: 32972178 [TBL] [Abstract][Full Text] [Related]
30. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. Hughes A; Clarson J; Tang C; Vidovic L; White DL; Hughes TP; Yong AS Blood; 2017 Mar; 129(9):1166-1176. PubMed ID: 28049640 [TBL] [Abstract][Full Text] [Related]
31. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. Jabbour E; Kantarjian H Am J Hematol; 2022 Sep; 97(9):1236-1256. PubMed ID: 35751859 [TBL] [Abstract][Full Text] [Related]
32. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation. Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245 [TBL] [Abstract][Full Text] [Related]
33. Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients. Nicolini FE; Dulucq S; Boureau L; Cony-Makhoul P; Charbonnier A; Escoffre-Barbe M; Rigal-Huguet F; Coiteux V; Varet B; Dubruille V; Lenain P; Rousselot P; Rea D; Guerci-Bresler A; Legros L; Liu J; Gardembas M; Ianotto JC; Turlure P; Johnson-Ansah H; Martiniuc J; Jardel H; Joly B; Zunic P; Henni T; Villemagne B; Berger MG; Cayssials E; Guilhot F; Larosa F; Guilhot J; Etienne G; Mahon FX Clin Cancer Res; 2019 Nov; 25(22):6606-6613. PubMed ID: 31292142 [TBL] [Abstract][Full Text] [Related]
34. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797 [TBL] [Abstract][Full Text] [Related]
35. Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia. Lejniece S; Udre I; Rivkina A Exp Oncol; 2017 Jul; 39(2):151-154. PubMed ID: 29483494 [TBL] [Abstract][Full Text] [Related]
36. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants. Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109 [TBL] [Abstract][Full Text] [Related]
37. Molecular analysis of the BCR-ABL1 kinase domain in chronic-phase chronic myelogenous leukemia treated with tyrosine kinase inhibitors in practice: study by the Nagasaki CML Study Group. Itonaga H; Tsushima H; Imanishi D; Hata T; Doi Y; Mori S; Sasaki D; Hasegawa H; Matsuo E; Nakashima J; Kato T; Horai M; Taguchi M; Matsuo M; Taniguchi H; Makiyama J; Sato S; Horio K; Ando K; Moriwaki Y; Sawayama Y; Ogawa D; Yamasaki R; Takasaki Y; Imaizumi Y; Taguchi J; Kawaguchi Y; Yoshida S; Joh T; Moriuchi Y; Nonaka H; Soda H; Fukushima T; Nagai K; Kamihira S; Tomonaga M; Yanagihara K; Miyazaki Y Leuk Res; 2014 Jan; 38(1):76-83. PubMed ID: 24262285 [TBL] [Abstract][Full Text] [Related]
38. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance. Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639 [TBL] [Abstract][Full Text] [Related]
39. Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor-1 inhibitor TM5614 combined with a tyrosine kinase inhibitor. Takahashi N; Kameoka Y; Onizuka M; Onishi Y; Takahashi F; Dan T; Miyata T; Ando K; Harigae H Cancer Med; 2023 Feb; 12(4):4250-4258. PubMed ID: 36151699 [TBL] [Abstract][Full Text] [Related]